When you start researching how ( back in 2015) this unbelievable group of scholars "targeted" NR2F6 to treat Cancer ( and other diseases), you realize that it's GENIUS! They have, and will receive more patents granted for each avenue of NR2F6. Interesting, they really DON'T need the major pharmaceuticals for a buyout ( The pharma's need RGBP). With the potential pay day on these patents, huge institutional investors would line up to fund the company. My point is that RGBP IS IN A GREAT POSITION, and will do possibly better if they DO NOT sell to a major Pharmaceutical.
Market Data 
Markets 
AI
